Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 16.12
(2.54%)
SEK 16.12
(2.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -146.56 Million SEK | -21.32% |
| 2023 | -120.8 Million SEK | -2.23% |
| 2022 | -118.17 Million SEK | -37.61% |
| 2021 | -85.88 Million SEK | -981.82% |
| 2020 | 9.73 Million SEK | 126.63% |
| 2019 | -36.56 Million SEK | 16.96% |
| 2018 | -44.03 Million SEK | -72.55% |
| 2017 | -25.52 Million SEK | 20.4% |
| 2016 | -32.05 Million SEK | -48.64% |
| 2015 | -21.56 Million SEK | -28.9% |
| 2014 | -16.73 Million SEK | -28.39% |
| 2013 | -13.03 Million SEK | 79.45% |
| 2012 | -63.42 Million SEK | -156.97% |
| 2011 | 111.33 Million SEK | 3857.64% |
| 2010 | -2.96 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -42.28 Million SEK | -2.36% |
| 2024 Q3 | -41.3 Million SEK | -38.49% |
| 2024 Q2 | -29.82 Million SEK | 6.86% |
| 2024 Q1 | -32.02 Million SEK | 17.32% |
| 2023 Q1 | -33.47 Million SEK | 22.93% |
| 2023 FY | -120.8 Million SEK | -2.23% |
| 2023 Q4 | -38.73 Million SEK | -63.81% |
| 2023 Q3 | -23.64 Million SEK | 5.23% |
| 2023 Q2 | -24.95 Million SEK | 25.47% |
| 2022 Q4 | -43.43 Million SEK | -147.26% |
| 2022 FY | -118.17 Million SEK | -37.61% |
| 2022 Q3 | -17.56 Million SEK | 5.58% |
| 2022 Q2 | -18.6 Million SEK | 52.55% |
| 2022 Q1 | -39.21 Million SEK | -38.32% |
| 2021 Q1 | 106 Thousand SEK | 100.81% |
| 2021 Q2 | -11.99 Million SEK | -11417.92% |
| 2021 Q3 | -32.65 Million SEK | -172.17% |
| 2021 FY | -85.88 Million SEK | -981.82% |
| 2021 Q4 | -28.34 Million SEK | 13.18% |
| 2020 Q1 | -6.74 Million SEK | 31.16% |
| 2020 Q3 | -7.04 Million SEK | -116.03% |
| 2020 Q4 | -13.11 Million SEK | -86.1% |
| 2020 Q2 | 43.97 Million SEK | 751.99% |
| 2020 FY | 9.73 Million SEK | 126.63% |
| 2019 Q4 | -9.79 Million SEK | -24.08% |
| 2019 Q1 | -8.46 Million SEK | 26.33% |
| 2019 FY | -36.56 Million SEK | 16.96% |
| 2019 Q2 | -10.41 Million SEK | -22.96% |
| 2019 Q3 | -7.89 Million SEK | 24.17% |
| 2018 Q3 | -12.58 Million SEK | -37.85% |
| 2018 FY | -44.03 Million SEK | -72.55% |
| 2018 Q4 | -11.49 Million SEK | 8.69% |
| 2018 Q2 | -9.13 Million SEK | 15.64% |
| 2018 Q1 | -10.82 Million SEK | -70.3% |
| 2017 FY | -25.52 Million SEK | 20.4% |
| 2017 Q4 | -6.35 Million SEK | 23.51% |
| 2017 Q1 | -4.44 Million SEK | 8.37% |
| 2017 Q2 | -6.42 Million SEK | -44.63% |
| 2017 Q3 | -8.31 Million SEK | -29.26% |
| 2016 FY | -32.05 Million SEK | -48.64% |
| 2016 Q1 | -4.3 Million SEK | -12.01% |
| 2016 Q2 | -4.69 Million SEK | -8.91% |
| 2016 Q3 | -18.2 Million SEK | -287.94% |
| 2016 Q4 | -4.85 Million SEK | 73.35% |
| 2015 Q4 | -3.84 Million SEK | 47.48% |
| 2015 Q3 | -7.32 Million SEK | -69.36% |
| 2015 Q2 | -4.32 Million SEK | 28.77% |
| 2015 Q1 | -6.07 Million SEK | -78.64% |
| 2015 FY | -21.56 Million SEK | -28.9% |
| 2014 Q4 | -3.39 Million SEK | 9.21% |
| 2014 Q2 | -4.56 Million SEK | 9.29% |
| 2014 Q3 | -3.74 Million SEK | 17.91% |
| 2014 Q1 | -5.02 Million SEK | -12.56% |
| 2014 FY | -16.73 Million SEK | -28.39% |
| 2013 Q1 | 812 Thousand SEK | 102.78% |
| 2013 Q4 | -4.46 Million SEK | -9.11% |
| 2013 FY | -13.03 Million SEK | 79.45% |
| 2013 Q3 | -4.09 Million SEK | 22.52% |
| 2013 Q2 | -5.28 Million SEK | -750.74% |
| 2012 Q1 | -13.25 Million SEK | 57.12% |
| 2012 Q4 | -29.22 Million SEK | -407.98% |
| 2012 Q2 | -15.19 Million SEK | -14.57% |
| 2012 Q3 | -5.75 Million SEK | 62.13% |
| 2012 FY | -63.42 Million SEK | -156.97% |
| 2011 Q1 | 96.8 Million SEK | 33.45% |
| 2011 FY | 111.33 Million SEK | 3857.64% |
| 2011 Q2 | 71.82 Million SEK | -25.81% |
| 2011 Q3 | -26.37 Million SEK | -136.72% |
| 2011 Q4 | -30.91 Million SEK | -17.24% |
| 2010 Q2 | -26.84 Million SEK | 0.0% |
| 2010 FY | -2.96 Million SEK | 0.0% |
| 2010 Q3 | -31.11 Million SEK | -15.9% |
| 2010 Q4 | 72.54 Million SEK | 333.12% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 41.134% |
| Ziccum AB (publ) | -21.56 Million SEK | -579.81% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -793.647% |
| BioArctic AB (publ) | 252.64 Million SEK | 158.014% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -17245.207% |
| Mendus AB (publ) | -100.65 Million SEK | -45.62% |
| Genovis AB (publ.) | 54.22 Million SEK | 370.299% |
| Intervacc AB (publ) | -93.57 Million SEK | -56.624% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -844.862% |
| Active Biotech AB (publ) | -46.48 Million SEK | -215.306% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 913.854% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -164.48% |
| Aptahem AB (publ) | -10.1 Million SEK | -1350.475% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 54.412% |
| Kancera AB (publ) | -65.04 Million SEK | -125.342% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -8.877% |
| Fluicell AB (publ) | -26.87 Million SEK | -445.284% |
| Saniona AB (publ) | -81.06 Million SEK | -80.802% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -1084.763% |
| Biovica International AB (publ) | -126.07 Million SEK | -16.256% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -244.823% |
| AcouSort AB (publ) | -17.48 Million SEK | -738.148% |
| Xintela AB (publ) | -57.23 Million SEK | -156.066% |
| Abliva AB (publ) | -96.54 Million SEK | -51.807% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 54.875% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -4081.655% |
| OncoZenge AB (publ) | -15.9 Million SEK | -821.689% |
| Amniotics AB (publ) | -29.07 Million SEK | -404.134% |
| 2cureX AB (publ) | -36.36 Million SEK | -303.066% |
| CombiGene AB (publ) | -36.3 Million SEK | -303.708% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -901.141% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 61.871% |
| Camurus AB (publ) | 532.35 Million SEK | 127.532% |
| Corline Biomedical AB | -1.78 Million SEK | -8097.26% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 18.918% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -251.623% |
| I-Tech AB | 24.43 Million SEK | 699.824% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 81.412% |
| Cyxone AB (publ) | -21.66 Million SEK | -576.64% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -38.316% |
| Biosergen AB | -27.26 Million SEK | -437.565% |
| Cantargia AB (publ) | -290.01 Million SEK | 49.463% |
| NextCell Pharma AB | -43.17 Million SEK | -239.495% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 18.918% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -757.304% |
| Nanologica AB (publ) | -69.96 Million SEK | -109.492% |
| SynAct Pharma AB | -224.49 Million SEK | 34.713% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -231.78% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -511.862% |
| LIDDS AB (publ) | -40.67 Million SEK | -260.346% |
| Lipum AB (publ) | -37.25 Million SEK | -293.426% |
| BioInvent International AB (publ) | -369.94 Million SEK | 60.381% |
| Alzinova AB (publ) | -16.52 Million SEK | -787.102% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 42.171% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -2192.528% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -27.369% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -627.777% |
| Simris Alg AB (publ) | -36.63 Million SEK | -300.074% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 52.785% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -32.145% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -1167.223% |